ASCO® 2024 Summary: "Treatment and Outcomes in Select Subpopulations With Breast Cancer"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Treatment and Outcomes in Select Subpopulations With Breast Cancer"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Lisa Carey

345 views

June 18, 2024

Comments 0

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

Communicating the Risk of Recurrence for Patients With HR+, HER2- Ea…

Feat. J. O’Shaughnessy

2024 ASCO® Annual Meeting Insights Hub: Breast Videos

ASCO 2024 Highlights: Insights From Key Abstracts on mBC

2024 ASCO® Annual Meeting Insights Hub

S. Aithal

168 views

2 months ago

ASCO® 2024 Insights: "Impact of ctDNA Surveillance on Clinical Care …

2024 ASCO® Annual Meeting Insights Hub

M. Lipsyc-Sharf

298 views

3 months ago

ASCO® 2024 Insights: "Genomic Alterations in HR+/HER2- Metastatic Br…

2024 ASCO® Annual Meeting Insights Hub

M. Bhave

464 views

4 months ago

View All

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

4.1K views

5 months ago

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.1K views

4 months ago

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

2.1K views

4 months ago

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, TROPI…

Insights from 2023 ASCO® Annual Meeting

P. Tarantino

8.2K views

1 year ago

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Total Health

R. O'Regan

1.3K views

8 months ago

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+ mBC?"

Insights from 2023 SABCS

S. Tolaney, H. Rugo

3.0K views

10 months ago

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

1.4K views

5 months ago

SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & Fulvestra…

Integrity CE

A. Bardia

1.5K views

9 months ago

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

1.5K views

2 months ago

Year in Review: Breast Cancer

Dana-Farber Cancer Institute

P. Tarantino

2.4K views

9 months ago

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

Memorial Sloan Kettering Cancer Center

K. Jhaveri

541 views

1 month ago

2023 Menopause Update

Yale School of Medicine

M. Minkin

9.0K views

1 year ago

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

721 views

1 month ago

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.9K views

7 months ago

Neoadjuvant Chemo for HR+ BC: Year in Review

Total Health

C. Ma

975 views

8 months ago

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

733 views

1 month ago

ASCO® 2023 Summary: "eBC Expert Panel Discussion on Key Trials Inclu…

Insights from 2023 ASCO® Annual Meeting

H. Rugo, K. Jhaveri

4.8K views

1 year ago

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Insights from ESMO Breast 2024 Annual Meeting

H. Rugo

1.2K views

5 months ago

SABCS 2023 Insights: "Biology or Stage? Tailoring Treatment for Prem…

Insights from 2023 SABCS

K. Kalinsky

1.8K views

11 months ago

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNOTE-75…

Insights from 2023 ESMO Annual Meeting

P. Tarantino

2.1K views

1 year ago

AUTOPLAY

Login

Login

Join VuMedi

ASCO® 2024 Summary: "Treatment and Outcomes in Select Subpopulations With Breast Cancer"

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Communicating the Risk of Recurrence for Patients With HR+, HER2- Ea…

2024 ASCO® Annual Meeting Insights Hub: Breast Videos

ASCO 2024 Highlights: Insights From Key Abstracts on mBC

ASCO® 2024 Insights: "Impact of ctDNA Surveillance on Clinical Care …

ASCO® 2024 Insights: "Genomic Alterations in HR+/HER2- Metastatic Br…

Recommended

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, TROPI…

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+ mBC?"

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & Fulvestra…

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

Year in Review: Breast Cancer

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

2023 Menopause Update

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Neoadjuvant Chemo for HR+ BC: Year in Review

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

ASCO® 2023 Summary: "eBC Expert Panel Discussion on Key Trials Inclu…

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

SABCS 2023 Insights: "Biology or Stage? Tailoring Treatment for Prem…

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNOTE-75…